Skip to content

Comparison of safety, effectiveness and serum inflammatory factor indexes of Saccharomyces boulardii versus Bifidobacterium triple viable in treating children with chronic diarrhea

Comparison of safety, effectiveness and serum inflammatory factor indexes of Saccharomyces boulardii versus Bifidobacterium triple viable in treating children with chronic diarrhea

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100046444
Enrollment
Unknown
Registered
2021-05-15
Start date
2021-06-21
Completion date
Unknown
Last updated
2022-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic diarrhea in children

Interventions

Group 3:Saccharomyces boulardii
Group 2:Bifidobacterium triple viable

Sponsors

Zhongda Hospital Affiliated to Southeast University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 8 Years

Inclusion criteria

Inclusion criteria: 1. The number of bowel movements is >= 3 times/day, and the stool characteristics are consistent with Bristol stool characteristics types 6 and 7; 2. The duration of diarrhea symptoms >= 2 weeks; 3. Aged 2 to 8 years; 4. Routine stool examination, no white blood cell or red blood cell count.

Exclusion criteria

Exclusion criteria: 1. Mucous stools or pus and blood stools; 2. Take other probiotics, antidiarrheal drugs or drugs that affect gastrointestinal motility within 2 weeks before being included in this study; 3. History of allergic reactions to probiotics.

Design outcomes

Primary

MeasureTime frame
Serum inflammatory factors;Treatment effect;Adverse reactions;

Countries

China

Contacts

Public ContactZhang Jiawei

Zhongda Hospital Affiliated to Southeast University

qingchenxiaolu87@163.com+86 15716175178

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026